Pyridoxal Phosphate Anhydrous

Summary

Pyridoxal Phosphate Anhydrous (CHEMBL82202) is a phase-3 clinical-stage small-molecule EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 5
• Chemistry: 247.14 Da · C8H10NO6P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL82202
Name	Pyridoxal Phosphate Anhydrous
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	1051
ChEBI	CHEBI:18405
Molecular formula	C8H10NO6P
Molecular weight	247.14
InChIKey	NGVDGCNFYWLIFO-UHFFFAOYSA-N

SMILES: CC1=NC=C(C(=C1O)C=O)COP(=O)(O)O

IUPAC name: (4-formyl-5-hydroxy-6-methyl-3-pyridinyl)methyl dihydrogen phosphate

ChEBI definition: The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.

Pharmacological roles (ChEBI): coenzyme, EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor, cofactor.

Other ChEBI roles (chemical / environmental): human metabolite, Escherichia coli metabolite, Saccharomyces cerevisiae metabolite, mouse metabolite.

Also known as: NSC-82388, Pyridoxal 5’-phosphate, Pyridoxal phosphate anhydrous, pyridoxal 5’-phosphate, Pyridoxal phosphate, SID29218058, Pyridoxal-5’-phosphate, pyridoxal-5’-phosphate, pyridoxal phosphate, MC-1

Parent form; salt/anhydrous children: CHEMBL3181870, CHEMBL3989490

Patent coverage: 9,047 distinct patent families (26,220 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 25,085 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Estrogen receptor, P2X purinoceptor 1, Prostaglandin G/H synthase 1, P2X purinoceptor 1, P2X purinoceptor 2, 3’,5’-cyclic-AMP phosphodiesterase 4A, Low molecular weight phosphotyrosine protein phosphatase.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 8 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P47824	5.52	EC50	3000	nM	CHEMBL_ACT_37539
PTGS1	5.17	AC50	6681	nM	CHEMBL_ACT_25206771
PTGS1	5.06	AC50	8661	nM	CHEMBL_ACT_25205841
P2RX1	5	IC50	10000	nM	CHEMBL_ACT_13278565

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04706013	PHASE3	RECRUITING	Oral Pyridoxal 5’-Phosphate for the Treatment of Patients With PNPO Deficiency
NCT00157716	PHASE2	COMPLETED	MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)
NCT00917293	PHASE2	TERMINATED	Safety and Efficacy of Pyridoxal 5’ -Phosphate in the Treatment of Tardive Dyskinesia
NCT03738943	EARLY_PHASE1	COMPLETED	Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults
NCT07469462	Not specified	RECRUITING	The Effects of High-dose Vitamin B6 on Depression and Anxiety Symptoms

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).